Exelixis Announces Phase II Trial Programs for Most Advanced Internally Developed Compounds

"Monday, August 15, 2005

Exelixis, Inc. (Nasdaq: EXEL) today announced plans for Phase II programs for its three most advanced internally generated development compounds, XL999, XL647, and XL784. XL999 and XL647 are anticancer compounds, currently in late Phase I trials and the company intends to begin a Phase II program for each of these compounds before the end of the year...

XL647 simultaneously inhibits the EGFR, HER2, and VEGFR RTKs in vitro. The compound is orally bioavailable in humans and a tablet dosage form has been developed for use in Phase II studies. XL647 is expected to enter initially into Phase II trials in patients with non-small cell lung cancer and breast cancer, tumors where the kinases inhibited by XL647 are known to play a role. Additionally, the company is considering combination trials of XL647 with other anticancer treatments to test the ability of the combination therapy to prolong progression free survival."